1.6 Frailty, Sarcopenia & Obesity in Liver Transplantation

Comprehensive Summary: Frailty, Sarcopenia & Obesity in Liver Transplantation

Lecture by Prof. Sanjaya Satapathy | UNETSis Medical Education Series

1. Main Clinical Topics Discussed

• Definitions and pathophysiology of frailty and sarcopenia in the context of chronic liver disease and liver transplantation
• Relationship between body composition (including obesity) and transplant outcomes
• Clinical assessment tools for frailty and sarcopenia
• Impact of sarcopenia on pre- and post-transplant mortality
• The principle of risk modification over exclusion in transplant candidacy evaluation

2. Key Learning Points, Guidelines & Recommendations

Core Principle:

• Frailty and sarcopenia predict outcomes independent of MELD score — two patients with identical MELD scores can have markedly different risk profiles based on functional status and muscle mass
• ABIM emphasis: Think dynamically; avoid rigid cutoffs

Definitions:

• Frailty: Decreased physiologic reserve, vulnerability to stressors, impaired functional status; reflects impaired muscle *contractile function*
• Sarcopenia (Greek: *sarx* = flesh, *penia* = loss): Loss of skeletal muscle *mass* and strength
• The two conditions frequently coexist and share a vicious cycle of deterioration

Shared Contributing Factors (Frailty & Sarcopenia):

• Inadequate caloric and protein intake
• Recurrent hospitalization
• Socioeconomic barriers to care
• Aging and physical inactivity

Unique Drivers:

• *Frailty*: Hepatic encephalopathy, refractory ascites, endocrine dysfunction
• *Sarcopenia*: Direct muscle wasting, bacterial translocation → inflammatory cytokines, elevated ammonia (impairs muscle function), reduced branched-chain amino acids (e.g., leucine), elevated myostatin, accelerated starvation state due to depleted glycogen, mitochondrial and ribosomal dysfunction

Liver Frailty Index (LFI):

• Composed of three tests: Hand grip strength, balance testing (side-by-side → semi-tandem → tandem), chair stand (5 repetitions)
• Classification:

- Non-frail: LFI < 3.2

- Pre-frail: LFI 3.2–4.5

- Frail: LFI ≥ 4.5

• Higher LFI correlates significantly with increased waitlist mortality

Assessment Tools for Sarcopenia:

3. Specific Clinical Data, Statistics & Study Results

Sarcopenia Prevalence in Cirrhosis (Meta-analysis, 23 studies):

• Prevalence range: 15%–57% across cohorts
• Pooled overall prevalence: 37.5% (95% CI: 32.4–42.8%)
• Higher in males (41.9%) vs. females (28.7%)
• Highest in alcohol-associated liver disease (49.6%) vs. non-alcoholic (33.4%)
• More prevalent in Child-Pugh C (46.7%), indicating worsening with disease severity

Survival Impact (Cumulative survival, sarcopenic vs. non-sarcopenic):

• 1-year survival: 93.4% (non-sarcopenic) vs. 76.6% (sarcopenic)
• 5-year survival: 74.2% (non-sarcopenic) vs. 45.3% (sarcopenic)
• Hazard ratio: 2.3 — sarcopenia more than doubles mortality risk